Home Cart Sign in  
Chemical Structure| 1604810-83-4 Chemical Structure| 1604810-83-4

Structure of THZ1
CAS No.: 1604810-83-4

Chemical Structure| 1604810-83-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

THZ1 is a selective and potent covalent CDK7 inhibitor with an IC50 of 3.2 nM. It also inhibits closely related kinases CDK12 and CDK13 and downregulates MYC expression.

Synonyms: THZ1

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of THZ1

CAS No. :1604810-83-4
Formula : C31H28ClN7O2
M.W : 566.05
SMILES Code : O=C(NC1=CC=CC(NC2=NC=C(Cl)C(C3=CNC4=C3C=CC=C4)=N2)=C1)C5=CC=C(NC(/C=C/CN(C)C)=O)C=C5
Synonyms :
THZ1
MDL No. :MFCD28167785
InChI Key :OBJNFLYHUXWUPF-IZZDOVSWSA-N
Pubchem ID :73602827

Safety of THZ1

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of THZ1

Hedgehog

Isoform Comparison

Biological Activity

Description
THZ1 is a potent and selective covalent inhibitor of CDK7 with an IC50 of 3.2 nM, affecting CDK12 and CDK13 at higher concentrations and leading to the downregulation of MYC expression.

In Vitro:

Cell Line
Concentration Treated Time Description References
KYSE510 cells 21 to 192 nM 3 days THZ1 treatment resulted in G2/M phase arrest, inhibition of cell proliferation, and induction of massive apoptosis PMC5912916
TE7 cells 21 to 192 nM 3 days THZ1 treatment resulted in G2/M phase arrest, inhibition of cell proliferation, and induction of massive apoptosis PMC5912916
Jurkat T-ALL cells 250 nM 4 hrs THZ1 completely inhibits the phosphorylation of the established intracellular CDK7 substrate RNAPII CTD at Ser-5 and Ser-7, with concurrent loss of Ser-2 phosphorylation at 250 nM in Jurkat cells PMC4244910
Loucy cells 250 nM 4 hrs THZ1 inhibits RNAPII CTD phosphorylation and causes cell cycle arrest in Loucy cells PMC4244910
Hela S3 cells 2.5 µM 5 hrs Ectopic expression of dox-inducible FLAG-CDK7 C312S, but not FLAG-CDK7 WT, in Hela S3 cells restored RNAPII CTD p-Ser 5/7 to near WT levels at concentrations of THZ1 up to 2.5 µM PMC4244910
SU-DIPG-VI 0.1 μM 72 hours THZ1 robustly reduced DIPG cell viability, with a median 72-hour IC50 of 56 nM. PMC5462626
SU-DIPG-XIII-P 0.1 μM 72 hours THZ1 robustly reduced DIPG cell viability, with a median 72-hour IC50 of 56 nM. PMC5462626
Ewing sarcoma cells 9.76 nM 72 hr THZ1 significantly inhibited the growth of Ewing sarcoma cells and induced apoptosis. PMC5846483
LNCaP cells 100 nM 6 hours THZ1 inhibited MED1 phosphorylation and prevented MED1 binding to AR, thereby suppressing AR-dependent transcriptional activity. PMC7202356
mTHP-1 cells 20-30 nM 0.5-1 hour To verify the impact of blocking CDK7 on inflaμMation, PMA-induced macrophages (mTHP-1 cells) were first treated with a concentration gradient of THZ1 to determine its safe range. PMC7780220
MDMs 30 nM 8 hours To detect the gene profiles after overexposure to LPS, MDMs were treated with 30 nM THZ1, and the results showed that THZ1 significantly suppressed the expression of inflaμMatory genes. PMC7780220
Jurkat cells 100 nM to 2 μM 6 hours Inhibition of CDK2 T-loop phosphorylation PMC6588464

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NOD-SCID gamma mice KYSE510 subcutaneous xenograft model Intraperitoneal injection 20 mg/kg/day Once daily THZ1 completely suppressed OSCC tumour growth in vivo, and no significant loss of body weight or other common toxic effects were observed PMC5912916
mice human T-ALL xenografted model 400 mg/kg/day once daily for 3 weeks THZ1 demonstrated efficacy against primary leukemia cells and in a bioluminescent xenografted model using the human T-ALL cell line, KOPTK1, when dosed twice daily (BID) at 10 mg/kg PMC4244910
mice DIPG xenograft model intraperitoneal injection 10 mg/kg Twice daily, for 24 days THZ1 treatment significantly increased the median survival of DIPG xenograft mice by approximately 20%. PMC5462626
Mice TC32 Ewing sarcoma xenografts Intraperitoneal injection 10 mg/kg twice daily for 29 days THZ1 as a single agent significantly impaired tumor progression and increased overall survival. PMC5846483
mice VCaP CRPC xenograft model intraperitoneal injection 10 mg/kg 5 days per week for 1 week THZ1 significantly inhibited tumor growth in the VCaP CRPC xenograft model and reduced plasma PSA levels, indicating that THZ1 effectively suppressed AR signaling in vivo. PMC7202356
mice Lewis lung cancer model intraperitoneal injection 10 mg/kg twice daily for 4 weeks The combination of THZ1 and antiPD-1 antibody showed a significant reduction in tumor burden compared to THZ1 or antiPD-1 alone, with no significant loss of body weight or other common toxic effects PMC7370470
C57BL/6 mice LPS-induced CRS model intraperitoneal injection 80 ng, 480 ng Single dose, 18 hours duration To evaluate the therapeutic effects of THZ1 in LPS-induced CRS model, the results showed that THZ1 significantly alleviated the inflammatory response and improved the survival rate of mice. PMC7780220
Nude mice A673 xenograft model Intraperitoneal (THZ1) and oral (olaparib) 10 mg/kg Twice daily for 40 days The combination of THZ1 and olaparib significantly inhibited tumor growth and extended survival without hematopoietic toxicity. PMC5846483

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.77mL

0.35mL

0.18mL

8.83mL

1.77mL

0.88mL

17.67mL

3.53mL

1.77mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories